NeurogesX Inc., a San Carlos, Calif.-based drug company focused on pain management therapies, priced 4 million common shares at $11 per share ($13-$15 range), for an IPO take of approximately $44 million. Morgan Stanley served as lead underwriter. It began trading on the Nasdaq under ticker symbol NGSX, and closed down around 6.8%
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
